Compare LSCC & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSCC | CORT |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 3.7B |
| IPO Year | 1989 | N/A |
| Metric | LSCC | CORT |
|---|---|---|
| Price | $84.96 | $46.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $82.18 | ★ $114.20 |
| AVG Volume (30 Days) | 1.7M | ★ 3.4M |
| Earning Date | 02-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.20 | ★ 0.87 |
| Revenue | $494,889,000.00 | ★ $741,172,000.00 |
| Revenue This Year | $4.26 | $21.70 |
| Revenue Next Year | $21.54 | $30.13 |
| P/E Ratio | $420.90 | ★ $52.25 |
| Revenue Growth | N/A | ★ 17.92 |
| 52 Week Low | $34.69 | $32.99 |
| 52 Week High | $89.92 | $117.33 |
| Indicator | LSCC | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 43.30 |
| Support Level | $82.52 | $34.06 |
| Resistance Level | $88.31 | $37.48 |
| Average True Range (ATR) | 3.49 | 1.99 |
| MACD | -0.24 | 2.25 |
| Stochastic Oscillator | 48.26 | 99.59 |
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.